Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15542047 | 0.81 | KDM4E (0.49) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL28314171 | 0.80 | SRC (0.47) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL15541690 | 0.78 | KDM4E (0.53) | KDM4EALDH1A1MAPTCYP3A4MEN1 | |
| SCHEMBL29950209 | 0.78 | KDM4E (0.53) | KDM4EALDH1A1MAPTCYP3A4MEN1 | |
| SCHEMBL30129469 | 0.77 | ALDH1A1 (0.37) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL27704559 | 0.76 | MAOB (0.71) | KDM4EALDH1A1MEN1KMT2AMAOA | |
| SCHEMBL2450078 | 0.75 | KDM4E (0.71) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL29076941 | 0.70 | KMT2A (0.55) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL1992305 | 0.69 | KDM4E (0.62) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL5459905 | 0.69 | KDM4E (1.00) | KDM4EALDH1A1MAPTCYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577257-A1 | METHOD AND SYSTEM FOR MATERIAL MODIFICATION | Edwards Lifesciences Corporation (US) | 2025-07-02 | — | — | EP | claimed |
| CN-120018869-A | Method and system for material modification | 爱德华兹生命科学公司 | 2025-05-16 | — | — | CN | claimed |
| WO-2024044071-A1 | METHOD AND SYSTEM FOR MATERIAL MODIFICATION | EDWARDS LIFESCIENCES CORPORATION (US) | 2024-02-29 | — | — | WO | claimed |
| US-20220283179-A1 | METHODS AND COMPOSITIONS FOR DETECTING PROTEIN TARGETS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-09-08 | — | — | US | claimed |
| WO-2017074937-A1 | AFFINITY PROBES FOR DEFINING PROTEIN-LIPID CONTACTS | THE CLEVELAND CLINIC FOUNDATION (US) | 2017-05-04 | — | — | WO | claimed |
| US-20170115280-A1 | AFFINITY PROBES FOR DEFINING PROTEIN-LIPID CONTACTS | THE CLEVELAND CLINIC FOUNDATION | 2017-04-27 | — | — | US | claimed |
| US-20250360172-A1 | MICROGEL-ENCAPSULATED IPSC-DERIVED NOTOCHORDAL CELLS FOR TREATMENT OF INTERVERTEBRAL DISC DEGENERATION AND DISCOGENIC PAIN | CEDARS-SINAI MEDICAL CENTER (US) | 2025-11-27 | — | — | US | disclosed |
| US-12466811-B2 | Mass spectrometry cleavable heterobifunctional photoactivated cross-linkers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250257391-A1 | ROLLING CIRCLE AMPLIFICATION COMPRISING CROSSLINKING AND DE-CROSSLINKING | 10X GENOMICS, INC. | 2025-08-14 | — | — | US | disclosed |
| US-20250213355-A1 | METHODS AND SYSTEMS FOR MATERIAL MODIFICATIONS USING LASER TECHNIQUES | EDWARDS LIFESCIENCES CORP (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4577257-A1 | METHOD AND SYSTEM FOR MATERIAL MODIFICATION | Edwards Lifesciences Corporation (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-120018869-A | Method and system for material modification | 爱德华兹生命科学公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119895052-A | Space histology based on bar code diffusion | 数码生物公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20180155720-A1 | ENGINEERED NUCLEIC ACID-TARGETING NUCLEIC ACIDS | CARIBOU BIOSCIENCES, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9816093-B1 | Engineered nucleic acid-targeting nucleic acids | CARIBOU BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2017136581-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATE | MEDITOPE BIOSCIENCES, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017074937-A1 | AFFINITY PROBES FOR DEFINING PROTEIN-LIPID CONTACTS | THE CLEVELAND CLINIC FOUNDATION (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20170115280-A1 | AFFINITY PROBES FOR DEFINING PROTEIN-LIPID CONTACTS | THE CLEVELAND CLINIC FOUNDATION | 2017-04-27 | — | — | US | disclosed |
| US-20160362667-A1 | CRISPR-Cas Compositions and Methods | CARIBOU BIOSCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| WO-2015097313-A1 | METAL CHELATION-BASED FLUORESCENT PROBES FOR PROTEIN OR OTHER BIOMOLECULE LABELING IN CELLS | THE UNIVERSITY OF HONG KONG (CN) | 2015-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466811-B2 | Mass spectrometry cleavable heterobifunctional photoactivated cross-linkers | JMJD7, DCLRE1A, PTMS | KDM4E 3100/4885ALDH1A1 3673/4885GAA 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.